Its shares have settled down since takeover rumours began earlier this week but InterMune is bracing itself for offers from suitors across the pharmaceutical industry. - News - PharmaTimes
by Kevin Grogan
www.pharmatimes.com/news/suitors_poised_to_bid_for_intermune_1002329Eisai is acquiring the US firm AkaRx in a deal which will give the Japanese drugmaker access to a mid-stage thrombocytopaenia drug. - News - PharmaTimes
by Kevin Grogan
www.pharmatimes.com/news/eisai_buys_akarx_for_$255_million_984073Moderna Therapeutics has caused a stir by raising a whopping $450 million, reportedly the largest-ever private financing round for any biotech. - News - PharmaTimes
by Kevin Grogan
www.pharmatimes.com/news/moderna_raises_massive_$450_million_970819Australia's Mayne Pharma is to buy Metrics, a privately-owned US-based provider of contract development services to the pharma industry in a deal worth up to $120 million. - News - PharmaTimes
by Kevin Grogan
www.pharmatimes.com/news/mayne_pharma_buys_metrics_976489As part of its strategy of expanding in growth markets, Takeda is establishing a subsidiary in Israel. - News - PharmaTimes
by Kevin Grogan
www.pharmatimes.com/news/takeda_sets_up_subsidiary_in_israel_1006206Vanda Pharmaceuticals has been stunned by a recommendation from European regulators that the US firm's schizophrenia drug Fanaptum should not get the green light. - News - PharmaTimes
by Kevin Grogan
www.pharmatimes.com/news/chmp_turns_down_vanda_schizophrenia_drug_976028AstraZeneca has acquired a cyclin-dependent kinase 9 inhibitor programme, targeting cancer and inflammatory diseases, from Germany's Probiodrug. - News - PharmaTimes
by Kevin Grogan
www.pharmatimes.com/news/az_expands_cancer_pipeline_with_probiodrug_pact_1001308Mundipharma and associate Purdue Pharmaceuticals have linked up with Spain’s Esteve to develop “important next-generation products” for the management of pain. - News - PharmaTimes
by Kevin Grogan
www.pharmatimes.com/news/mundipharma_and_esteve_sign_major_pain_pact_970859UCB has opened the doors to its 65 million euro biotechnology plant in Belgium. - News - PharmaTimes
by Kevin Grogan
www.pharmatimes.com/news/ucb_launches_biotech_facility_in_belgium_976631Indian drugmakers are "ideally placed to capitalise on the growing biosimilars market". - News - PharmaTimes
by Kevin Grogan
www.pharmatimes.com/news/india_set_for_biosimilars_bonanza_979644
